ライフサイエンスコーパス: event

1 ere used to isolate sustained air pollution "events".

2 primary outcome (composite of cardiovascular events).

3 Bay Hawai'i during the 2015 coral bleaching event.

4 pacted by a recent whole-genome triplication event.

5 gs derived from the whole-genome duplication event.

6 had at least one treatment-emergent adverse event.

7 ode can experience a life-threatening asthma event.

8 an), 6378 participants had experienced a CHD event.

9 (ESCRTs) mediate diverse membrane remodeling events.

10 in the context of detecting outlier splicing events.

11 ) had treatment-related grade 3 or 4 adverse events.

12 drug in terms of treatment-emergent adverse events.

13 and motor proteins disrupt this sequence of events.

14 onses given the rarity of observed predation events.

15 when inferring indirect relationships among events.

16 for binding, rather than specific signalling events.

17 quately account for nonischemic diseases and events.

18 the experimentally reported dynamics of SWR events.

19 ation and activation of downstream signaling events.

20 proaches and the pathobiology of these novel events.

21 stream of PAR4 activation that leads to such events.

22 ation with subsequent cardiovascular disease events.

23 bal reward state as well as specific outcome events.

24 easured by the occurrence of serious adverse events.

25 rder to derive the distribution of recurring events.

26 s important for many developmental migration events.

27 mpened the organism's reaction to subsequent events.

28 hospital vascular complications and bleeding events.

29 nagement of adults with acute cardiovascular events.

30 0 kilobases (kb)) inversions but not smaller events.

31 rrelation analyses across pairs of packaging events.

32 ranslation, thus blocking further initiation events.

33 el (MSL) changes and extreme sea-level (ESL) events.

34 g, yet preventable hospital-acquired adverse events.

35 l infarction at the expense of more bleeding events.

36 ow well-known TRMs and related TF co-binding events.

37 specific origin sites established by dynamic events.

38 +)-sensitive fraction of spontaneous release events.

39 between-group differences in serious adverse events.

40 rocedure MALE hospitalization and subsequent events.

41 were conducted to assess risk of GI adverse events.

42 analysis and interpretation of arm selection events.

43 charge date to identify and classify adverse events.

44 oductive function can be shaped by childhood events.

45 djudication, not just those for the reported events.

46 reclassification for CHD but not for stroke events.

47 iscontinuation due to inefficacy and adverse events.

48 hus enforcing a temporally ordered series of events.

49 k coronary plaque and risk of cardiovascular events.

50 spatial and temporal coverage of ecological events.

51 frequent duplication and/or gene conversion events.

52 .02 [95% CI, 0.92-1.14] in CLUE II [n = 1497 events]).

53 s in LOS had a higher risk of severe adverse events [1.22 (1.11-1.34)] and death [1.17 (1.04-1.32)].

54 ratory distress syndrome (25%), neurological events (25%), arrhythmias (22%), and venous thromboembol

55 -up of 6.6 years, there were 8 major adverse events: 6 relapses, 1 treatment-related death (from sept

56 lysed the risk ratio (RR) for major vascular events (a composite of cardiovascular death, myocardial

57 tration (FDA) drug reviews, all reported CVD events across latter-phase (II and III) trials supportin

58 Multiple upstream events activate the pathway, but how each controls this

59 The signaling events activate the transcription factors AP-1 and NF-ka

60 ol group reported at least 1 serious adverse event (adjusted RR, 1.72 [95% CI, 0.7 to 4.3]).

61 Serious adverse events (AEs) occurred in 10% of imipenem/relebactam and

62 d study of ophthalmic immune-related adverse events (AEs), including determination of incidence and r

63 ons (LRs) and systemic events (SEs), adverse events (AEs), serious AEs, newly diagnosed chronic medic

64 Pembrolizumab-related adverse events affected 71% of the patients, and 4 (7%) were gra

65 breast cancer who experienced cardiovascular events after cancer diagnosis had increased risk of recu

66 hes in assessing total ischemic and bleeding events after percutaneous coronary intervention in the G

67 Adverse events, although mild, were more common in both peppermi

68 Time-to-first-event analysis considers only the first event irrespecti

69 uding the time to first symptomatic skeletal event and the time to first use of cytotoxic chemotherap

70 ; 35% nonwhite), there were 858 incident CVD events and 1209 deaths over a median of 13.0 y.

71 ive" state that contributes to fast synaptic events and a "constrained pre-active" state that does no

72 ere were no deaths or device-related adverse events and a significant reduction in right ventricular

73 e (TRAPP) complexes regulate key trafficking events and are required for autophagy.

74 ceded by and influenced by symmetry breaking events and cell polarization.

75 Thromboembolic events and intraoperative rupture were reported in 113 o

76 ecause of the potential for profound adverse events and large variations in survival outcome.

77 events and were able to detect reproductive events and menopause in all females.

78 a total of 17 FUS treatments with no adverse events and neither cognitive nor neurological worsening.

79 ress matrix may influence centrally mediated events and on possible therapeutic interventions to corr

80 Adverse events and pharmacokinetic measurements were assessed.

81 ibition on fatal and non-fatal heart failure events and renal outcomes in all randomly assigned patie

82 nic pain may sap the motivation for positive events and stimuli.

83 e emitter reporting single-molecular tension events and the associated cellular force nanoscopy (CFN)

84 Extreme events and the related anomalous statistics are ubiquito

85 ds, examining the relationship between these events and those observed by smFRET.

86 Both genetic programs arising from oncogenic events and transcriptional programs and epigenomic event

87 from 15 individuals with known life history events and were able to detect reproductive events and m

88 e preferentially retained after a recent WGD event, and expansion of CHS genes is likely associated w

89 w ratcheted processivity emerges from pulsed events, and how tissue-level mechanics are the coordinat

90 points were device related death or adverse events, and major bleeding within 72 hours after BEC dir

91 ctive treatment developed serious infectious events, and two (10%) developed diverticular disease com

92 tion; grade 5 = more than one decompensating event; and grade 6 = death.

93 [95% CI, 0.87-1.56] in the NHANES [n = 1012 events] and 1.02 [95% CI, 0.92-1.14] in CLUE II [n = 149

94 These intron retention events appear not to alter overall expression levels of

95 Those who report SDs prior to a traumatic event are at greater risk for developing PTSD; highlight

96 ecasts for the occurrence of El Nino/La Nina events are also performed and assessed via information-t

97 and transcriptional programs and epigenomic events are important in providing the necessary metaboli

98 Extreme heat wave events are now causing ecosystem degradation across mari

99 nts that cooperate with known somatic driver events are poorly understood.

100 Arterial cardiovascular events are the leading cause of death in patients with J

101 These events are usually preceded by and influenced by symmetr

102 lping to ensure that emotionally significant events are well remembered.

103 etic studies point to the second protonation event as being rate-determining.

104 lead to the activation of apoptotic cellular events as evidenced by both terminal deoxynucleotidyl tr

105 able cause for grade 3-4 hematologic adverse events, as they occurred before CAR-NKT cell infusion, a

106 gical and disease initiation and progression events associated with Chr1- and Chr10-directed AMD.

107 ssor protein which controls many tumorigenic events associated with the hedgehog (hh) signaling pathw

108 ent at ~34.1-33.9 Ma and the Oi-1 glaciation event at ~33.8-33.6 Ma.

109 ligocene transition (EOT): the EOT-1 cooling event at ~34.1-33.9 Ma and the Oi-1 glaciation event at

110 these self-reports, medical records for all events at every hospital where the patient reported rece

111 irway epithelium, supporting the notion that events at the airway epithelial surface are critical for

112 and effect patterns, even for different rain events at the same site.

113 elated cardiometabolic syndrome encompassing events before, during the acute phase, and subsequently

114 There was no difference in adverse events between randomised groups.

115 sult of previously undescribed recombination events between ssDNA and ssRNA viruses.

116 sterior Medial cortical network in signaling event boundaries.

117 ducing reagents as well as electron transfer events by electric current.

118 n RAS and KIT and the widespread copy number events by which TGCT is characterised.

119 KT/DDKT) March 15-April 30, 2020 to expected events calculated from preepidemic data January 2016-Feb

120 ling ( EF >5% and ESV 10%) and heart failure event/cardiovascular death.

121 rity versus low-severity cases (0.98 vs 0.40 events/case, P < 0.001).

122 thin 60 weeks after transplantation; adverse event coding was centralised.

123 rimary cardiovascular end point of major CVD events (composite of myocardial infarction, stroke, and

124 Patients were followed for ASCVD events comprising CHD, cerebrovascular disease, and PAD

125 Adverse events consisted primarily of elevated liver tests (6%),

126 (21%) with grade >=3 immune-related adverse events, consisting of asymptomatic laboratory abnormalit

127 cert with NF-kappaB-mediated transcriptional events, control the metabolism at several levels.

128 the Common Terminology Criteria for Adverse Events (CTCAE), version 5, and its relationship with par

129 the Common Terminology Criteria for Adverse Events (CTCAE; v4.03) classification.

130 Our aim was to investigate the CVD events (CVDEs) and survival between the patients with FM

131 etration site couples two decisive infection events, cytosol arrival and disassembly, and suggest car

132 Combined adverse event data and BCAR episodes from all six CTG trials rev

133 of both vascular complications and bleeding events decreased over time (P value for trend test <0.00

134 include the incidence of high-grade adverse events, defined by the Common Terminology Criteria for A

135 Proportions of patients with adverse events did not differ significantly among groups.

136 the Common Terminology Criteria for Adverse Events, do not provide information on the time profile o

137 Incidences of adverse events, drug continuation, implantable cardioverter defi

138 event (OR 1.55, 95% CI: 1.03-2.33), adverse events due to decreased appetite (OR 3.56, 95% CI: 1.94-

139 52 (6%) versus 27 (15%) experiencing outcome events during follow-up, respectively.

140 le range) lossless multiple light scattering events, enabled by a highly porous (>99.99%) non-absorbi

141 ich is difficult to interpret for a positive event, especially in the presence of competing risks.

142 is associated with increased cardiovascular events, especially in high-risk populations.

143 However, on typical air pollution events, fire emissions contributed as high as 50-75% (80

144 ncidence of cardiovascular and renal disease events, follow-up information was obtained and confirmed

145 s) for the effects of radiotherapy timing on event-free survival and subgroup interactions were combi

146 and were able to obtain updated results for event-free survival for 2153 patients recruited between

147 edian follow-up of 44 months (26-53), 4-year event-free survival was 59% (95% CI 48-73); 69% (54-87)

148 y secondary endpoints were overall survival, event-free survival, and progression-free survival and s

149 The primary endpoints were event-free survival, overall response, and overall survi

150 Four-year event-free survival, relapse-free survival, and overall

151 m mtDNA was also subjected to additional HGT events from diverse angiosperm lineages, including large

152 Adverse events from these agents might affect the ability of pat

153 torms can affect lakes via short-term runoff events from watersheds and physical mixing of the water

154 al and pharmacokinetic measures, and adverse events graded 2 or higher.

155 ting tempo of epizootic and zoonotic disease events has made it seem as if disease is on the rise.

156 In addition, these events have been linked to flash droughts and can play a

157 ncers, but the factors associated with these events have been poorly explored.

158 These events have many astrophysical implications; for example

159 ssociated with a severe or critical COVID-19 event (HR, 1.10; 95% CI, 0.73 to 1.60).

160 HR], 1.06 [95% CI, 0.89-1.26]), HF (n = 1396 events; HR, 0.91 [95% CI, 0.76-1.09]), or CKD (n = 2433

161 0.91 [95% CI, 0.76-1.09]), or CKD (n = 2433 events; HR, 0.98 [95% CI, 0.65-1.11]).

162 Tear film stability is the key event in ocular surface diseases.

163 eutrophils (PMNs), which serves as the first event in the acute respiratory distress syndrome (ARDS).

164 n of the retromer complex system is an early event in the development of the AD-like pathology and co

165 the LMA group and as not having had such an event in the face-mask group.

166 were counted as having had a primary outcome event in the LMA group and as not having had such an eve

167 h resulting from a treatment-related adverse event in the subcutaneous daratumumab group (febrile neu

168 ores were not associated with cardiovascular events in 357 882 unrelated individuals from UK Biobank.

169 cing data identifies non-productive splicing events in 7,757 protein-coding human genes, of which 1,2

170 Extreme weather events in Asia have been occurring with increasing frequ

171 py number changes, mutations, and structural events in cancer samples.

172 reen seaweeds survived these extreme climate events in isolated refugia, and diversified in benthic e

173 ine the prevalence of venous thromboembolism events in patients infected with severe acute respirator

174 nclear if the flu vaccine exacerbates immune events in patients treated with immune checkpoint inhibi

175 ween LGE presence and adverse cardiovascular events in patients with dilated cardiomyopathy in a mult

176 ion of integrated representations of related events in subfield CA(1) Furthermore, memory reactivatio

177 elevated frequency and intensity of hypoxic events in the coastal zone, which have the potential to

178 ere is also the potential for severe adverse events, including cytokine release syndrome (CRS).

179 The NRE is impacted by extreme weather events, including recent increases in precipitation and

180 propose to separate spatially overlapping MB events into sub-populations, each with sparser MB concen

181 py-number states, a considerable fraction of events involve multiple chromosomes and additional struc

182 The most recent introgression event involved a massive and asymmetrical movement of ge

183 irst-event analysis considers only the first event irrespective of its severity.

184 the cleavage product from this fragmentation event is released into the conditioned medium of cells e

185 mechanism of, and connection between, these events is unclear.

186 itment to inflamed arteries is implicated in events leading to mortality following MI.

187 a single successful latent cell reactivation event leads to observable viremia after a period of expo

188 f PD-L2 and identify a specific evolutionary event linked to its appearance.

189 higher risk of major adverse cardiovascular events (MACE) compared with those without PAD.

190 Treatment-related adverse events (mainly mild or moderate local reactions) were re

191 eural representations of regularly occurring events may be foundational for performing complex cognit

192 ork for predicting both when and where these events may occur.

193 tly associated with incident ASCVD (n = 1386 events; median follow-up, 25.2 years; hazard ratio [HR],

194 registration, and poor reporting of adverse events, methods of sequence generation and allocation co

195 ents with osteoporosis defined by a clinical event, namely a fragility fracture, or with an osteoporo

196 A primary end-point event occurred in 187 patients (6.8%) in the colchicine

197 A secondary composite 1 event occurred in 76 patients (23.0%) receiving aspirin

198 ths (IQR 71.3 to 71.7), the primary endpoint event occurred in 79 patients (31 in the 40 Gy group, 27

199 wever, it is unclear whether super-spreading events occurred during the early outbreak phase, as has

200 Nonfatal serious adverse events occurred in 12/72 (16.7%) in the oral group and 1

201 Intraoperative events occurred more frequently in high-severity versus

202 ained from 253,397 patients, in which 99,371 events occurred.

203 tinction was the most severe mass extinction event of the Phanerozoic and was followed by a several m

204 ayed positive excursion during major El Nino events of 1983, 1997/98 and 2015/16, indicating drought

205 The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study has reported an inc

206 ypothesis that the physiologically impactful events of parturition and menopause are recorded in dent

207 The incidence of dental and skin adverse events of special interest was higher with the 10-mg and

208 (3.8%) patients had a total of 26 thrombotic events, of which 22 occurred in the first 14 days after

209 ing task and organized past and future world events on a canvas according to their representation of

210 Although we experience thousands of distinct events on a daily basis, relatively few are committed to

211 ideal system for studying the impact of WGD events on speciation and evolutionary adaptation.

212 We describe 2 large (>5 kb) recombination events, one of which arose in its current host, demonstr

213 demonstrated the advantages of moving these events online.

214 rmation on the time profile of these adverse events or reflect the continuous, lower grade symptomati

215 a (OR 5.37, 95% CI: 1.17-24.65), any adverse event (OR 1.55, 95% CI: 1.03-2.33), adverse events due t

216 .65, 95% CI: 1.04-6.80), any serious adverse event (OR 2.30, 95% CI: 1.18-4.48), serious adverse even

217 R 2.61, 95% CI: 1.38-4.96) or due to adverse events (OR 2.65, 95% CI: 1.04-6.80), any serious adverse

218 gnitude and frequency of large precipitation events, or deluges.

219 r during El Nino-Southern Oscillation (ENSO) events originating in the Eastern Tropical Pacific (ETP)

220 hough there were no differences in immediate event outcomes or intra-arrest hemodynamics.

221 n)=0.02; 2.7% versus 1.7% for major vascular events, P(interaction)<0.0001).

222 ling relations in the delay suffered by both event participants and other citizens doing their usual

223 of recurrent stroke or TIA: 2.32 versus 0.75 events per 100 patient-years (hazard ratio [HR], 3.05 [9

224 in the placebo group (incidence, 2.5 vs. 3.6 events per 100 person-years; hazard ratio, 0.69; 95% con

225 We used the apnea-hypopnea index (events per hour) to define obstructive sleep apnea sever

226 vents per patient-year; glargine group, 0.46 events per patient-year; estimated rate ratio, 1.09; 95%

227 ive impairment) were low (icodec group, 0.53 events per patient-year; glargine group, 0.46 events per

228 nalyses) aimed to detect any combinations of events predicting poor outcome as defined by a cumulativ

229 nce that deficiency for this phosphorylation event prevents condensin II release from chromatin.

230 n, with the guided series of differentiation events producing heterogeneous cell populations that dis

231 rable responses and had a manageable adverse events profile in patients with relapsed or refractory D

232 verages (PTA), and procedure-related adverse events rated by the Common Terminology Criteria for Adve

233 ith similar hypertrophy severity and adverse event rates as observed with truncating variants.

234 We compare adverse event rates associated with IV iron vs red cell transfus

235 Among individuals with high CVH, event rates were low across sociodemographic subgroups (

236 sed teaching involves reflection on recalled events (recall-assisted reflection).

237 This phosphorylation event reduced eIF2alpha binding to PERK and selectively

238 ed desensitization; however, how degradation events regulate BCR functions in GCs is unclear.

239 OR 2.30, 95% CI: 1.18-4.48), serious adverse events related to abnormal liver function tests (OR 11.1

240 on the attentional-orienting-sensitive N2pc event-related potential component.

241 In previous EEG research enhanced event-related potentials (ERPs) in the late-positive pot

242 ask while recording response times (RTs) and event-related potentials, focusing on the attentional-or

243 e rates and potential immune-related adverse events remain two major challenges.

244 The physiological relevance of this cleavage event remains unclear, although it is thought to inhibit

245 A mean of 2.92 violent events resulted in cumulative absolute increase in Rt of

246 Most adverse events resulted only in symptoms (77%) and 36% were judg

247 vas according to their representation of the event's temporal position relative to themselves.

248 ed with a risk of procedural serious adverse events (SAE) and exposure to ionizing radiation.

249 ulture-conversion rates, and serious adverse events (SAEs) during treatment.

250 -reported local reactions (LRs) and systemic events (SEs), adverse events (AEs), serious AEs, newly d

251 was measured before and during a low-stress event (sham clipping) and compared with heart rate varia

252 pressed after renal ischemia-reperfusion, an event that induces kidney injury and fibrosis.

253 ly related AFC lineage into An. funestus, an event that predated and plausibly facilitated its subseq

254 KDM6A) and activation of the RTK FGFR3, two events that commonly cooccur in muscle invasive bladder

255 We previously described the regulatory events that control the timely synthesis of Ndc80.

256 ncer diagnoses in children(1,2), and genetic events that cooperate with known somatic driver events a

257 re of the transformations at the core of the events that define the morphological shape for C. jejuni

258 This work alters our understanding of the events that drive the activation of class B receptors.

259 cell development and highlight the molecular events that govern hemogenic specification of vascular e

260 uma resuscitations are complex critical care events that present patient safety-related risk.

261 Asthma exacerbations are inflammatory events that rarely result in full hospitalization follow

262 While this is often attributed to events that took place in the early 1990s, consciousness

263 own regulator of physiological and oncogenic events, the role of PKI proteins in these pathways has r

264 multaneously identify immune-related adverse events, there are several challenges in interpreting the

265 different than those of recurrent ischaemic events; therefore, recognising these predictors may help

266 ctuated by speciation pulses, during warming events throughout the Phanerozoic and 2) that conifer ex

267 analysis links multiple alternative splicing events together and allows for better estimates of the a

268 However, the molecular events underlying HIV neuropathogenesis remain elusive,

269 Thus, it appears that as events unfold mentally, structures are dynamically react

270 was born at term and experienced no cardiac events until 4 years of age, at which point she was hosp

271 rising CHD, cerebrovascular disease, and PAD events until December 31, 2017.

272 r adverse cardiovascular and cerebrovascular events was higher in the FFR-guided PCI versus the CABG

273 tive temporal ordering of cell and molecular events was not absolute, suggesting cell programmes reac

274 participants with local or systemic adverse events was similar in the two groups.

275 wise method to capture all available adverse events, we first extracted data on myelodysplastic syndr

276 ression-free survival (PFS), OS, and adverse events were also assessed.

277 Analyses of skeletal-related events were also done in the intention-to-treat populati

278 endothelial cell count, and possible adverse events were assessed at least 12 months postoperatively.

279 No serious adverse events were attributed to dihydroartemisinin-piperaquine

280 me pharmacology and plume-like neural Ca(2+) events were consistent with action-potential-independent

281 All patients had engraftment, and adverse events were consistent with effects of the preparative c

282 Reported systemic and local events were mild and transient.

283 All treatment-related adverse events were mild or moderate in severity and similar acr

284 ILD events were more common among those with early/mild ILA

285 Serious adverse events were more common with systematic treatment.

286 or balloon-assisted coiling, thromboembolic events were more frequent than were intraoperative ruptu

287 Adverse events were mostly mild and equally distributed (15/23 [

288 t common treatment-related grade 3-4 adverse events were neutropenia (15 [50%] of 30 patients), incre

289 tolerated and no study drug-related adverse events were recorded.

290 Adverse events were reported in 58.4% of patients; most (94.4%)

291 Eight serious adverse events were reported with capsular release and two with

292 alted the trial when the numbers of clinical events were significantly lower among children receiving

293 Serious procedure-related adverse events were uncommon.

294 Multiple spacer integration is a rare event which significance for immunity is poorly understo

295 atial and temporal location of key molecular events, which may guide the evaluation of new therapies.

296 There were no unexpected adverse events with (177)Lu-PSMA retreatment.

297 with highly variable SI respond to stressful events with increases in SI.

298 ere were decreased Optimizer-related adverse events with the 2-lead system compared with the 3-lead s

299 ntified 13,149 high-confidence cassette exon events with variable incorporation across samples.

300 tection of infections and for hotspots (RACD events yielding >=1 additional infection).